Tscan therapeutics to participate in the 5th annual evercore isi healthconx conference

Waltham, mass., nov. 22, 2022 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced that management will participate in a virtual fireside chat at the 5th annual evercore isi healthconx conference on tuesday, november 29, 2022 at 10:55 a.m. et.
TCRX Ratings Summary
TCRX Quant Ranking